Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2005

View Archived Issues

Mechanisms underlying SERP-1 mediated inhibition of monocytic adhesion and migration

Preclinical efficacy of GRN-163 in lung cancer

Liposomal encapsulation improves dexamethasone's profile

Novel highly potent and selective TACE inhibitor disclosed

Tesaglitazar reduces the incidence of metabolic syndrome in hypertriglyceridemic patients

Avalon submits IND for AVN-944 for cancer

Anturol begins phase II study for overactive bladder syndrome

Intrac changes name to Javelin Pharmaceuticals

IPdR enters phase I cancer study

GlaxoSmithKline to acquire ID Biomedical

IND approved for clinical testing of Elacyt for cancer

Ardana holds pre-IND meeting for Teverelix LA

Xcytrin studied for second-line treatment of recurrent metastatic NSCLC

CE Mark approval for Taxus Liberte stent

BMS-740808: A novel factor Xa inhibitor with in vivo efficacy and good PK profile

Lateral hypothalamus orexin neurons: new targets for addiction

Exubera recommended for approval

Novel SARMs developed by Bristol-Myers Squibb

New therapeutic agents for cancer disclosed in recent patents

KSP inhibitor blocks tumor growth in mice

Update on darifenacin in overactive bladder

New data on the antiarrhythmic activity of AZD-7009

Astellas Pharma discloses novel therapeutic agents for bone disorders

Sorafenib submitted for European approval for advanced kidney cancer

FDA advisory committee votes to recommend Pargluva for type 2 diabetes

Biovail receives FDA approval for once-daily tramadol

New agents for treating hepatitis C infection disclosed by Japan Tobacco

Immunosuppressant S1P1 receptor agonists prepared and tested at Merck & Co.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...